학력 및 경력사항

• 울산대학교 의과대학 박사
• 울산대학교 의과대학 석사
• 한림대학교 의과대학 졸업

• 2022-현재  | 이대목동병원 호흡기내과 임상조교수
• 2020-2022  | 서울아산병원 호흡기내과 임상강사
• 2017-2020  | 서울아산병원 내과 전공의
• 2013-2014  | 서울아산병원 인턴

• 대한폐암학회 정회원
• 대한중환자의학회 평생회원
• 대한내과학회 정회원
• 대한결핵및호흡기학회 정회원

•  The safety and efficacy of SNK01 (autologous natural killer cells) in combination with cytotoxic chemotherapy and/or cetuximab after failure of prior tyrosine kinase inhibitor in non-small cell lung cancer: nonclinical mouse model and phase I/IIa clinical study.  Journal for ImmunoTherapy of Cancer. 2024-02. 
•  Prognostic Factors for Predicting Post-COVID-19 Condition in Patients With COVID-19 in an Outpatient Setting.  Journal of Korean Medical Science. 2024-01. 
•  The Real-World Outcome of First Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Multicenter Prospective Cohort Study.  Cancer Research and Treatment. 2023-10. 
•  Blood Krebs von den Lungen-6 levels predict treatment response to antifibrotic therapy in patients with idiopathic pulmonary fibrosis.  Respiratory Research. 2022-12. 
•  Impact of gender on response to immune checkpoint inhibitors in patients with non-small cell lung cancer undergoing second- or later-line treatment.  Translational Lung Cancer Research. 2022-09. 
•  The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in South Korea.  Journal of Korean Medical Science. 2022-04. 
•  Changes in blood Krebs von den Lungen-6 predict the mortality of patients with acute exacerbation of interstitial lung disease.  Scientific Reports. 2022-03. 
•  Different prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective study.  TRANSLATIONAL LUNG CANCER RESEARCH. 2021-06. 
•  The Effect of Simultaneous Pulmonary Rehabilitation during Thoracic Radiotherapy for Malignant Diseases.  TUBERCULOSIS AND RESPIRATORY DISEASES. 2021-02. 
•  Efficacy of natural killer cell activity as a biomarker for predicting immunotherapy response in non‐small cell lung cancer.  THORACIC CANCER. 2020-11. 
•  Natural Killer Cells as a Potential Biomarker for Predicting Immunotherapy Efficacy in Patients with Non-Small Cell Lung Cancer.  TARGETED ONCOLOGY. 2020-04. 
•  Effect of medical thoracoscopy‐guided intrapleural docetaxel therapy to manage malignant pleural effusion in patients with non‐small cell lung cancer: A pilot study.  THORACIC CANCER. 2019-08. 

• [건강이야기] 폐결절, 폐암의 씨앗일 수 있습니다 2023-03-17